Table 1.
Median responses ordered by significance in each experimental group
| Treatment | Cytokine | Median T2 | Quartiles T2 | P T0‐T2 | Q |
|---|---|---|---|---|---|
| EPIHIGH | IL‐1α | 7.5 | 3.6–58.1 | 0.001 | 0.0126 |
| CXCL1 | 83.5 | 24.8–186.5 | 0.0015 | 0.0135 | |
| GCSFa | 2.6 | 2.5–8.0 | 0.003 | 0.0180 | |
| IL‐6 | 18.6 | 2.8–45.6 | 0.0046 | 0.0207 | |
| EPILOW | MIP‐1α | 8.1 | 7.8–10.0 | 0.0015 | 0.027 |
| DFO | CXCL1 | 34.95 | 18.4–54.0 | 0.0001 | 0.0009 |
| IL‐6 | 3.49 | 2.6–9.6 | 0.0001 | 0.0009 | |
| IP‐10a | 2.15 | 1.9–2.7 | 0.0016 | 0.0096 | |
| DFO/EPI/NOREPI | IL‐6 | 4.36 | 2.2–20.8 | 0.0005 | 0.009 |
Data shown for differences between baseline and the 2 hr sample collection. Median and 25–75% Quartiles (Most sample populations were nonparametric). P = raw P from Kruskal Wallis Test/Wilcoxon post hoc test. Q = Benjamani–Hochberg adjusted P value for False Discovery Rate <0.2. Ordered by minimum Q value in each group.
EPI, epinephrine; NOREPI, norepinephrine; DFO, deferoxamine treatment
a
Statistically significant but the median at T2 was <1 pg/mL greater than average T0 and therefore was considered to be biologically unimportant.